The 2 major requirements for adrenergic blocking activity of the haloalkyl amine series of compounds were: an appropriate aromatic substituent, and a β-haloalkyl group capable of forming an ethylenimonium intermediate, the species directly responsible for the blockade; both must be present for activity.To evaluate the haloalkyl group and adrenergic blockade per se in protecting against exptl. hemorrhagic shock (in dogs and rats), 5 members of the series were examinedThese were phenoxybenzamine (I), N-benzyl-N-ethyl-β-chloroethylamine (II), N-phenoxyisopropyl-N-ethylaminoethanol (III, SKF-5331), N,N-dibenzylaminoethanol (IV, GD-12), and N-phenoxyisopropylN-benzylaminoethanol (V, SKF-1010).Thus, IV and V are hydrolysis products of dibenamine and I, resp., with neither adrenergic blocking activity nor a reactive β-halogen.A dose of 0.125, 0.25, or 1.0 mg. of I/kg. markedly reduced mortality without significantly reducing bleeding volumesPretreatment with II appeared to reduce the mortality rate (but it is not considered an expression of a specific antishock effect), and increased both the blood pressure and hematocrit.These effects suggest that increased sympathetic nervous system activity may have contributed to both the mortality and decreased blood volume No protection was provided by III, IV, and V at 10 mg./kg.